Increased uPA activity associated with increased metastatic activity seems well accepted and uPA and other members of the urokinase plasminogen activator system (including uPAR and PAI-1) have been selected as novel targets for potential tumour therapies [17]. The gene discussed is PLAU; the disease is neoplasm.